SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Angelo Antonini, Werner Poewe, Adenosine A2A receptor antagonists in Parkinson's disease: still in the running, The Lancet Neurology, 2014, 13, 8, 748

    CrossRef

  2. 2
    Annalisa Pinna, Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued, CNS Drugs, 2014, 28, 5, 455

    CrossRef

  3. 3
    Luca Antonioli, Balázs Csóka, Matteo Fornai, Rocchina Colucci, Endre Kókai, Corrado Blandizzi, György Haskó, Adenosine and inflammation: what's new on the horizon?, Drug Discovery Today, 2014,

    CrossRef

  4. 4
    Silvia Cerri, Giovanna Levandis, Giulia Ambrosi, Elena Montepeloso, Gian Filippo Antoninetti, Rafael Franco, José Luis Lanciego, Younis Baqi, Christa E. Müller, Annalisa Pinna, Fabio Blandini, Marie Therese Armentero, Neuroprotective Potential of Adenosine A2A and Cannabinoid CB1 Receptor Antagonists in an Animal Model of Parkinson Disease, Journal of Neuropathology & Experimental Neurology, 2014, 73, 5, 414

    CrossRef

  5. 5
    Izaskun Villar-Menéndez, Fabiana Nuñez, Sara Díaz-Sánchez, José Luis Albasanz, Jaume Taura, Víctor Fernández-Dueñas, Isidre Ferrer, Mairena Martín, Francisco Ciruela, Marta Barrachina, Striatal adenosine A2A receptor expression is controlled by S-adenosyl-L-methionine-mediated methylation, Purinergic Signalling, 2014,

    CrossRef

  6. 6
    Shin-ichi Uchida, Tomomi Tashiro, Mika Kawai-Uchida, Akihisa Mori, Peter Jenner, Tomoyuki Kanda, The Adenosine A2A-Receptor Antagonist Istradefylline Enhances the Motor Response of L-DOPA Without Worsening Dyskinesia in MPTP-Treated Common Marmosets, Journal of Pharmacological Sciences, 2014, 124, 4, 480

    CrossRef

  7. 7
    Fabrizio Stocchi, Therapy for Parkinson’s Disease: What is in the Pipeline?, Neurotherapeutics, 2014, 11, 1, 24

    CrossRef

  8. 8
    Juan C. Giugni, Michael S. Okun, Treatment of advanced Parkinsonʼs disease, Current Opinion in Neurology, 2014, 27, 4, 450

    CrossRef

  9. 9
    Adolfo Ramirez-Zamora, Eric Molho, Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions, Expert Review of Neurotherapeutics, 2014, 14, 1, 93

    CrossRef

  10. 10
    Albert Y. Hung, Michael A. Schwarzschild, Treatment of Parkinson’s Disease: What’s in the Non-dopaminergic Pipeline?, Neurotherapeutics, 2014, 11, 1, 34

    CrossRef

  11. 11
    Santiago Perez-Lloret, Marcelo Merello, Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant, Expert Opinion on Pharmacotherapy, 2014, 15, 8, 1097

    CrossRef

  12. 12
    Lars Brichta, Paul Greengard, Marc Flajolet, Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems, Trends in Neurosciences, 2013, 36, 9, 543

    CrossRef

  13. 13
    Susan H. Fox, Non-dopaminergic Treatments for Motor Control in Parkinson’s Disease, Drugs, 2013, 73, 13, 1405

    CrossRef

  14. 14
    Carlos Zúñiga-Ramírez, Federico Micheli, Preladenant: an adenosine A2Areceptor antagonist for Parkinson’s disease, Future Neurology, 2013, 8, 6, 639

    CrossRef